Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia

References

• National Center for Emerging and Zoonotic Infectious Diseases/Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant enterobacteriaceae (CRE). 2015.
   Google Scholar
• Morrill HJ, Pogue JM, Kaye KS, et al. Treatment options for carbapenem-resistant enterobacteriaceae infections. Open Forum Infect Dis. 2015;2(2):ofv050. .
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase–producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant pseudomonas aeruginosa. Mayo Clin Proc. 2011 Mar;86(3):250–259.
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano E, Berger S, et al. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis. 2015;15(1):395. .
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, et al. The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151.
   Web of Science ®Google Scholar
• Karaiskos I, Galani I, Souli M, et al. β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15(2):133–149.
   PubMed Web of Science ®Google Scholar
• de Souza Mendes C. Pipeline of known chemical classes of antibiotics. Antibiotics 2013;2(4):500–534.
   Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed. Lancet Infect Dis. 2016 Jun;16(6):661–673. .
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016 Sep;63(6):754–762. .
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380–1389. .
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018 Mar;18(3):285–295. .
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016 Dec;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. .
   PubMed Web of Science ®Google Scholar
• Yao X, Doi Y, Zeng L, et al. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis. 2016 Mar;16(3):288–289.
   PubMed Web of Science ®Google Scholar
• Liu -Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161–168.
   PubMed Web of Science ®Google Scholar
• Rojas LJ, Salim M, Cober E, et al. Colistin resistance in carbapenem-resistant klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis. 2017;64(6):711–718.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Montero JG, Paiva JA. When antibiotic treatment fails. Intensive Care Med. 2018;44(1):73–75. Available from: http://link.springer.com/10.1007/s00134-017-4962-2.
   PubMed Web of Science ®Google Scholar
• Colombian Health Technology Assessment Institute. Guidelines for the economic evaluation of healthcare technologies in Colombia. Bogotá D.C.: IETS; 2014 [ cited 2019 Mar 22]. Available from: http://www.iets.org.co/manuales/Manuales/Manual%20Evaluacion%20economica.pdf.
   Google Scholar
• DANE. Projection of the Colombian census 2005–2020; 2007 [cited 2018 Apr 16]. 225. Available from: https://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf.
   Google Scholar
• Garcia-Hernandez A, Mayrhofer T. Quality-of-life-adjusted hazard of death: a formulation of the quality-adjusted life-years model of use in benefit-risk assessment. Value Health. 2014 Mar 1;17(2):275–279.
   PubMed Web of Science ®Google Scholar
• Song Y, Tai JHY, Bartsch SM, et al. The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine. 2012 May 21;30(24):3675–3682. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X12004070?via%3Dihub.
   PubMed Web of Science ®Google Scholar
• Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001 Feb 1;32(3):e47–52. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/318492.
   PubMed Web of Science ®Google Scholar
• Central Bank of Colombia. Market representative exchange rate [Internet]; 2019. [cited 2018 Apr 19]. Available from: http://www.banrep.gov.co/es/-estadisticas.
   Google Scholar
• National Social Security Council for Health. SOAT; 2019. Tariff Manual. 2019.
   Google Scholar
• Colombian Social Security Institute. Resolution 1896 de 2001. Tariff manual ISS; 2001. Available from: https://lexsaludcolombia.files.wordpress.com/2010/10/tarifas-iss-2001.pdf.
   Google Scholar
• Tribiño G, Maldonado C, Segura O, et al. Direct costs and clinical aspects of adverse drug reactions in patients admitted to a level 3 hospital internal medicine ward. redalyc.org; 2006. Available from: https://www.redalyc.org/html/843/84326105/.
   Google Scholar
• Online Procurement System SECOP II [Internet]; 2019. Available from: https://www.colombiacompra.gov.co/sites/cce_public/files/cce_infografias/aviso_papeleria.pdf.
   Google Scholar
• Statistical Department of Colombia DANE. Gross domestic product –GDP- per capita. [cited 2018 Apr 19]. Available from: http://www.banrep.gov.co/es/pib.
   Google Scholar
• Alvarez C, Gómez C, Rodriguez T, et al. Impact of a program for the prudent use of antibiotics in a tertiary care hospital in Bogotá, Colombia, Colombia. Rev Médica Sanitas. 2017;20(2):75–82.
   Google Scholar
• Pallares CJ, Cataño JC. Impact of the rational use of antimicrobials in a tertiary clinic in Colombia. Rev Chil Infectología. 2017 Jun;34(3):205–211.
   PubMed Web of Science ®Google Scholar
• Raitano M, Gabriele S, Granaglia E, et al. The impact of death-related costs on health-care expenditure: a survey [Internet]; 2006 [cited 2019 Jun 5]. Available from: http://aei.pitt.edu/9487/2/9487.pdf.
   Google Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014 Jul;59(1):88–94.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017 Feb;49(2):233–238. .
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. 2019 Jan;68(3):355–364. .
   PubMed Web of Science ®Google Scholar
• Sfeir M, Satlin M, Calfee DP, et al. Cost-effectiveness of ceftazidime–avibactam compared with colistin for treatment of carbapenem-resistant enterobacteriaceae bacteremia and pneumonia. Open Forum Infect Dis. 2018 Nov 26;5(suppl_1):S539–40. Available from: https://academic.oup.com/ofid/article/5/suppl_1/S539/5207575.
   Google Scholar
• Office of Health Economics. The bacterial challenge: time to react; 2011 [cited 2018 Jul 17]. Available from: www.ecdc.europa.eu
   Google Scholar
• Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options; 2010 [cited 2018 Jul 17]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2640028.
   Google Scholar